Extended Abstract
Authors: Jean Hansen (Univeristy of Iowa, Iowa City, IA) , Jean-Marie Stephan (University of Iowa, Iowa City, IA) , Michelle Freesmeier (University of Iowa, Iowa City, IA) , David P Bender (University of Iowa, Iowa City, IA) , Koen De Geest , Anna Button (University of Iowa, Iowa City, IA) , Michael J. Goodheart (University of Iowa, Iowa City, IA)
The American Society of Clinical Oncology recommends that full weight-based doses of chemotherapy be used to treat obese patients with cancer. However, many oncologists limit the dose of chemotherapy based on ideal body weight or a maximum body surface area (BSA) of m2. The objective of our study is to determine how weight-based chemotherapy dosing affects toxicity, treatment delays, and laboratory values in a cohort of obese gynecologic cancer patients at our institution. We hypothesize that full weight-based dosing in obese patients does not increase adverse chemotherapy outcomes.
Keywords: chemotherapy, obesity, dosage
How to Cite: Hansen, J. , Stephan, J. , Freesmeier, M. , Bender, D. P. , De Geest, K. , Button, A. & Goodheart, M. J. (2013) “The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients”, Proceedings in Obstetrics and Gynecology. 3(3). doi: https://doi.org/10.17077/2154-4751.1235